Michail Ignatiadis

15.5k total citations · 2 hit papers
128 papers, 6.6k citations indexed

About

Michail Ignatiadis is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michail Ignatiadis has authored 128 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 76 papers in Cancer Research and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michail Ignatiadis's work include Cancer Genomics and Diagnostics (45 papers), Breast Cancer Treatment Studies (38 papers) and Cancer Cells and Metastasis (37 papers). Michail Ignatiadis is often cited by papers focused on Cancer Genomics and Diagnostics (45 papers), Breast Cancer Treatment Studies (38 papers) and Cancer Cells and Metastasis (37 papers). Michail Ignatiadis collaborates with scholars based in Belgium, Italy and United States. Michail Ignatiadis's co-authors include Christos Sotiriou, Stefanie S. Jeffrey, Martine Piccart, George W. Sledge, Christine Desmedt, Benjamin Haibe‐Kains, Françoise Rothé, Mark Lee, Sherene Loi and Vassilis Georgoulias and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Michail Ignatiadis

115 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liquid biopsy enters the clinic — implementation issues and future challenges

2021 744 citations Michail Ignatiadis, Stefanie S. Jeffrey et al. profile →
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

2008 654 citations Pratyaksha Wirapati, Christos Sotiriou et al. Breast Cancer Research profile →

Peers

Countries citing papers authored by Michail Ignatiadis

Since Specialization

Citations

This map shows the geographic impact of Michail Ignatiadis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michail Ignatiadis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michail Ignatiadis more than expected).

Fields of papers citing papers by Michail Ignatiadis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michail Ignatiadis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michail Ignatiadis. The network helps show where Michail Ignatiadis may publish in the future.

Co-authorship network of co-authors of Michail Ignatiadis

This figure shows the co-authorship network connecting the top 25 collaborators of Michail Ignatiadis. A scholar is included among the top collaborators of Michail Ignatiadis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michail Ignatiadis. Michail Ignatiadis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial 2025 ·Radiotherapy and Oncology ·Alex De Caluwé, (unknown), Kim Cao, (unknown), Vincent Remouchamps, (unknown), (unknown), Igor Bessières, (unknown), (unknown), Dirk Van Gestel, Isabelle Desmoulins, Michail Ignatiadis, Emanuela Romano, Laurence Buisseret, Martine Piccart, (unknown), Ákos Gulybán, Philip Poortmans	2
2	EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe 2024 ·European Journal of Cancer ·Michail Ignatiadis, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Fátima Cardoso, (unknown), David Cameron	2
3	2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC) 2024 ·Immuno-Oncology Technology ·(unknown), (unknown), (unknown), (unknown), Isabelle Desmoulins, Emanuela Romano, Vincent Remouchamps, (unknown), (unknown), Cédric van Marcke, (unknown), Michail Ignatiadis, Martine Piccart, Denis Larsimont, John Stagg, Christos Sotiriou, Roberto Salgado, Laurence Buisseret	0
4	338TiP EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) 2024 ·Annals of Oncology ·Michail Ignatiadis, Emmanouil Saloustros, (unknown), (unknown), Ciara M. Kelly, Evangelia Razis, (unknown), (unknown), (unknown), (unknown), (unknown), Sònia Pernas, Barbara Bussels, M. Hanssens, (unknown), (unknown), (unknown), (unknown), Coralie Poncet, W Janni	2
5	Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study. 2024 ·Journal of Clinical Oncology ·Matteo Lambertini, Eva Blondeaux, (unknown), Elisa Agostinetto, Anne‐Sophie Hamy, Hee Jeong Kim, Maria Alice Franzoi, Rinat Bernstein‐Molho, Florentine Hilbers, Katarzyna Pogoda, Hans Wildiers, Jyoti Bajpai, Michail Ignatiadis, Halle C. F. Moore, Ann H. Partridge, Kelly‐Anne Phillips, Angela Toss, Christine Rousset‐Jablonski, Carmen Criscitiello, Judith Balmañà	1
6	International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor. 2024 ·Journal of Clinical Oncology ·(unknown), Michail Ignatiadis, Carlos H. Barrios, François‐Clément Bidard, Binghe Xu, (unknown), Jason Gong, (unknown), Prashanth Gopalakrishna, Hope S. Rugo	2
7	Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis 2024 ·ESMO Open ·Guilherme Nader Marta, Marta Monteforte, Elisa Agostinetto, Michela Cinquini, Diogo Martins-Branco, (unknown), Antonio Llombart‐Cussac, Javier Cortés, Michail Ignatiadis, Valter Torri, Giovanni Apolone, Vera Cappelletti, Giancarlo Pruneri, Evandro de Azambuja, Serena Di Cosimo	24
8	Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse 2022 ·JCO Precision Oncology ·(unknown), Elisa Agostinetto, Matteo Lambertini, Françoise Rothé, Hsin-Ta Wu, Mustafa Balcioglu, Ekaterina Kalashnikova, Delphine Vincent, (unknown), Andrea Gombos, (unknown), Isabelle Veys, Ahmad Awada, Himanshu Sethi, Alexey Aleshin, Denis Larsimont, Christos Sotiriou, David Venet, Michail Ignatiadis	48
9	Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis 2022 ·npj Breast Cancer ·Françoise Rothé, David Venet, Dieter Peeters, Ghizlane Rouas, Mattia Rediti, Dominiek Smeets, Floriane Dupont, Peter J. Campbell, Diether Lambrechts, Luc Dirix, Christos Sotiriou, Michail Ignatiadis	15
10	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer 2021 ·npj Breast Cancer ·Andrea Gombos, David Venet, Lieveke Ameye, Peter Vuylsteke, Patrick Neven, Vincent R. Richard, François P. Duhoux, Jean‐François Laes, Françoise Rothé, Christos Sotiriou, Marianne Paesmans, Ahmad Awada, Thomas Guiot, Patrick Flamen, Martine Piccart, Michail Ignatiadis, Géraldine Gebhart	14
11	Predictive factors for cancer-associated thrombosis in a large retrospective single-center study 2019 ·Supportive Care in Cancer ·(unknown), Ahmad Awada, Marianne Paesmans, Michel Moreau, Jean Klášterský, (unknown), Michail Ignatiadis, Nuria Kotecki	12
12	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer 2019 ·European Journal of Cancer ·(unknown), (unknown), Madeline Pe, Corneel Coens, Francesca Martinelli, Katarzyna Pogoda, Galina Velikova, Vesna Bjelic‐Radisic, Fátima Cardoso, Étienne Brain, Michail Ignatiadis, Martine Piccart, Geertjan van Tienhoven, Robert E. Mansel, Hans Wildiers, Andrew Bottomley	46
13	Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility 2015 ·Clinical Cancer Research ·Michail Ignatiadis, Mark Lee, Stefanie S. Jeffrey	288
14	CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now? 2015 ·Clinical Cancer Research ·Isabelle Gingras, Christine Desmedt, Michail Ignatiadis, Christos Sotiriou	18
15	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer 2015 ·BMC Medicine ·Amir Sonnenblick, Sylvain Brohée, Debora Fumagalli, Delphine Vincent, David Venet, Michail Ignatiadis, Roberto Salgado, Gert Van den Eynden, Françoise Rothé, Christine Desmedt, Patrick Neven, Sibylle Loibl, Carsten Denkert, Heikki Joensuu, Sherene Loi, Nicolas Sirtaine, Pirkko‐Liisa Kellokumpu‐Lehtinen, Martine Piccart, Christos Sotiriou	44
16	Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis 2013 ·PLoS ONE ·Hatem A. Azim, Sandeep K. Singhal, Michail Ignatiadis, Christine Desmedt, Debora Fumagalli, Isabelle Veys, Denis Larsimont, Martine Piccart, Stefan Michiels, Christos Sotiriou	3
17	Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling 2012 ·Clinical Cancer Research ·Hatem A. Azim, Stefan Michiels, Philippe L. Bédard, Sandeep K. Singhal, Carmen Criscitiello, Michail Ignatiadis, Benjamin Haibe‐Kains, Martine Piccart, Christos Sotiriou, Sherene Loi	278
18	Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer 2011 ·Endocrine Related Cancer ·Philippe L. Bédard, Sandeep K. Singhal, Michail Ignatiadis, Ian Bradbury, Benjamin Haibe‐Kains, Christine Desmedt, Sherene Loi, Dean B. Evans, Stefan Michiels, J. Michael Dixon, William R. Miller, Martine Piccart, Christos Sotiriou	6
19	Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer 2008 ·Clinical Cancer Research ·Michail Ignatiadis, Galatea Kallergi, Maria Ntoulia, Maria Perraki, Stella Apostolaki, Maria Kafousi, Grigorios Chlouverakis, Efstathios N. Stathopoulos, Evi Lianidou, Vassilis Georgoulias, Dimitris Mavroudis	181
20	Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures breakdown → 2008 ·Breast Cancer Research ·Pratyaksha Wirapati, Christos Sotiriou, Susanne Kunkel, Pierre Farmer, Sylvain Pradervand, Benjamin Haibe‐Kains, Christine Desmedt, Michail Ignatiadis, Thierry Sengstag, Frédéric Schütz, Daniel R. Goldstein, Martine Piccart, Mauro Delorenzi	654

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact